@evoquant.bsky.social
Evoquant uses AI and bioinformatics to harness microbes, exploring billions of years of evolution to uncover new drug compounds and accelerate treatments for cancer, infectious diseases, and rare conditions. https://evoquantbio.com/
Photo of bacteria colonies growing on agar
Evoquant's first set of bacterial strains are growing. We now have several strains in culture as we begin evaluating our novel strategy for obtaining bioactive and novel natural products.
Photo is of one of the strains growing on a minimal agar media.
Evoquant received SBIR funding from the NIH in 2025 to develop new/better methods for finding anti-cancer and antibacterial small molecules produced by bacteria
With success, we would apply for a Phase 2 grant, which would allow the company to stay alive & commercialize. Unfortunately...
Evoquant is planning (registered today) to attend the Stanford Drug Discovery Symposium (SDDS 2026), with @chasingmicrobes.bsky.social presenting a poster.
First time attending and looking forward to it.
Evoquant is planning (registered today) to attend the Stanford Drug Discovery Symposium (SDDS 2026), with @chasingmicrobes.bsky.social presenting a poster.
First time attending and looking forward to it.
The SBIR program has not been renewed by Congress and therefore THERE ARE NO SBIR applications at NIH or elsewhere. NIH can't even issue "noncompeting continuation awards for existing projects until the SBIR/STTR program is reauthorized."
America is giving up on small business and Science.
Evoquant received SBIR funding from the NIH in 2025 to develop new/better methods for finding anti-cancer and antibacterial small molecules produced by bacteria
With success, we would apply for a Phase 2 grant, which would allow the company to stay alive & commercialize. Unfortunately...
Otherwise, it resolves to classic. Between versions of the AWS CLI, auto resolution criteria may change. To guarantee use of a specific transfer client, set the preferred_transfer_client configuration variable to the appropriate transfer client listed below. classic - Use the builtin, Python-based transfer client that supports all s3 commands, parameters, and most configuration values. crt - Use the AWS Common Runtime (CRT) transfer client when possible. It is a C-based S3 transfer client that can improve transfer throughput. Currently, the CRT transfer client does not support all of the functionality available in the classic transfer client. The list below details what functionality is currently not supported by the crt transfer client option and the corresponding behavior of the AWS CLI if it is configured to prefer the crt transfer client: S3 to S3 copies - Falls back to using the classic transfer client Region redirects - Transfers fail for requests sent to a region that does not match the region of the targeted S3 bucket. max_concurrent_requests, max_queue_size, multipart_threshold, and max_bandwidth configuration values - Ignores these configuration values.
I have been struggling with transfers in AWS between EC2 and S3 being way slower than the advertised EC2 bandwidth
Last week I learned about:
aws configure set s3.preferred_transfer_client crt
and now transfers are super duper fast.
The more you know
Screenshot of evoquantbio.com showing the text: EvoQuant LLC AI & Bioinformatics for Next-Generation Natural Product Drug Discovery Contact Us
🤩 evoquantbio.com 🤩
27.09.2025 14:30 — 👍 1 🔁 0 💬 0 📌 0
Public Health Relevance Statement This research addresses challenges in predicting bioactivity in natural product drug discovery by leveraging advanced AI, computational biology, and multi-omics knowledge graphs. This approach has the potential to accelerate the discovery of new, effective drugs for treating a range of conditions, including cancer, infections, and immune-related diseases, by identifying promising leads that could inform the next generation of therapeutics.
🚀 Evoquant has been awarded a $300k Small Business Grant from the National Institutes of Health for our project:
"Leveraging Large-Scale Bioinformatics & AI for Natural Product Drug Discovery and Target Selection"
Hitting the ground running 🏃and excited for the year to come!